Drug intelligence / Profile preview

AVI001

Development stage: Preclinical
Lead developer: Avipero
Modality: Antibody-Based Therapeutics
Administration: Intradermal Injection

Overview

AVI001 is an anti-beta1 integrin antibody under development by AVIPERO Ltd. This therapeutic agent is being investigated for its potential applications in cancer, age-related diseases, and skin rejuvenation. Its mechanism of action involves targeting and modulating beta1 integrin, a crucial cell adhesion molecule involved in various physiological and pathological processes, including cell proliferation, migration, and tissue remodeling. By interfering with beta1 integrin function, AVI001 aims to inhibit tumor growth, prevent metastasis, and promote the regeneration of cartilage and skin.

Targets

ITGB1 (Integrin beta-1)

Beyond the preview

Go deeper on AVI001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AVI001.

Explore the full profile